Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Google Secures Pentagon AI Deal for Classified Projects 
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
